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ABSTRACT  
Progressive multifocal leukoencephalopathy is a currently untreatable infection of the 
brain. Here, we demonstrate in two patients that treatment with interleukin-7, JCV 
capsid protein VP1 and a toll-like receptor 7 agonist used as adjuvant, was well 
tolerated, showed a very favorable safety profile and unexpected efficacy that 
warrants further investigation. 
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INTRODUCTION 
Progressive multifocal leukoencephalopathy (PML) is a life-threatening opportunistic 
infection of the brain caused by JC polyoma virus (JCV) [1] that occurs in various 
states of immunusuppression. The occurrence of PML in conditions of decreased 
CD4+ T cell numbers or function with resolution following their restoration [2] and 
immunological studies from brain-infiltrating T cells [3] strongly support the 
importance of these immune cells in controlling JCV infection. JCV-specific CD8+ 
cytotoxic T cells also play an important role in controlling this infection and have been 
linked to recovery from PML [4]. The role of antibodies is less clear, since they are 
frequently present before and at onset of PML [5]. Currently, there is no specific 
antiviral- or other drug to treat PML, and the only option is to restore protective 
immunity. The hematopoietic growth factor interleukin-7 (IL-7) is crucial for 
homeostatic T cell proliferation [6] and restores T cell function including virus-specific 
immunity [7]. Since vaccines induce antigen-specific immune responses, we 
reasoned that a therapeutic vaccine against JCV along with IL-7 treatment for 
general immune restoration might be effective by preferentially expanding JCV-
specific CD4+ T cells over other specificities. Here, we have treated two PML 
patients, who suffered from hereditary or acquired immunocompromise, with three 
subcutaneous injections of recombinant human IL-7 (r-hIL-7, CYT107) and a 
therapeutic vaccine consisting of JCV VP1 protein in combination with a topically 
administered toll-like receptor 7 (TLR7) agonist as adjuvant [8]. 
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METHODS 
Ethics Statement 
Both patients received the above treatment as "Compassionate Use". The term 
"Compassionate Use" refers to use of a non-approved drug or biological/chemical 
compound outside the framework of a clinical trial. The physician acts here in the 
scope of her/his medical license and takes complete responsibility for the prescribed 
therapy. When using a non-approved medication, the patient must be adequately 
informed and special authorization at the local Agency for Therapeutic Products 
obtained. Both patients were treated in full compliance with regulatory requirements 
in Germany and Switzerland. Patients and relatives were informed of the risks of the 
treatment including death from PML-IRIS and signed an informed consent. 
Patients 
Clinical information, neuroimaging- (MRI), virological- and immunological findings are 
summarized in Supplementary Table I. Both patients significantly deteriorated during 
the 12 months between diagnosis and treatment, and cerebrospinal fluid (CSF) JCV 
DNA remained positive during this time. Both patients were HIV negative. 
Treatment Regimen and Follow-up 
Patients have been treated with three subcutaneous (s.c.) injections of glycosylated 
recombinant human IL-7 (r-hIL-7; 10μg/kg body weight, CYT107, Cytheris S.A., 
Paris, France), three s.c. injections of 1 mg of recombinant JCV VP1 protein (Life 
Science Inkubator, Bonn, Germany) and topical imiquimod cream at the s.c. injection 
site (5%, Aldara®, MEDA Pharm, Germany), a TLR7/8 agonist used as adjuvant [8]. 
Treatment protocol is summarized in Figure (upper scheme). 
Tolerability and safety were assessed by clinical and laboratory adverse events 
(AEs, Institute of Clinical Chemistry, University Medical Center Hamburg Eppendorf, 
and the Institute of Clinical Chemistry, Hematology- and Neurology Clinics, University 
Hospital Zürich). Efficacy assessment included JCV DNA load, MRI, clinical 
observation and immunological testing. Cranial MRI examinations (T1 pre- and post 
gadolinium-; proton density (PD)/T2-; fluid attenuated inversion recovery (FLAIR)-, 
and diffusion-weighted images) were performed at the Department of 
Neuroradiology, University Medical Center Hamburg-Eppendorf, and the Institute for 
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Neuroradiology, University Hospital Zurich. Scripps neurological rating scale (SNRS) 
score was used to assess the clinical status (SNRS, 100 normal - 0 dead). 
Quantification of JCV Viral Load 
Viral load was quantified in the CSF by quantitative PCR (qPCR) of JCV T antigen as 
previously described [9]. 
Proliferative Assays 
Proliferative response of peripheral blood mononuclear cell (PBMCs) against VP1 (2 
µg/mL, [10]) and tetanus toxoid (TTx, 10 µg/mL, Novartis Behring, Marburg, 
Germany,) was tested in a 7-day 3H-thymidine incorporation assay, and stimulatory 
indices (SI) calculated as: mean counts per minute (cpm) with protein / mean cpm 
unstimulated wells. Proliferation was also determined by flow cytometry using 
CellTrace™ CFSE kit (Invitrogen, Darmstadt, Germany) in PBMCs seeded with VP1 
protein (2 μg/mL) for six days, labeled with CFSE and restimulated or not with VP1. 
After five days cells were stained with anti-CD4 (Biolegend, San Diego, CA), anti-
CD3 (eBioscience, San Diego, CA), anti-CD25 (Biolegend), and anti CD45RO 
(Biolegend). Samples were acquired using LSR-II and LSR-Fortessa flow cytometers 
(BD, Franklin Lakes, NJ) and data analyzed using FACS Diva Software (BD). 
ELISA for VP1-Specific Antibodies  
VP1-specific IgG titers in CSF/serum were determined as previously described [11]. 
Samples were pre-adsorbed with soluble BKV VP1 to compete potentially 
crossreactive antibodies. Virus-specific antibody indices (AI) were calculated as 
previously described [12]. Values of AI ≥ 1.5 indicate intrathecal antigen-specific 
antibody synthesis. 
Statistical Analysis 
Statistical analyses were performed with Prism 5.02 (GraphPad Software Inc., San 
Diego, CA). Descriptive statistics are reported as mean ± SEM. Comparisons of 
three groups and more were assessed by one-way ANOVA with Bonferroni’s 
correction for multiple comparisons. P-values < 0.05 were considered statistically 
significant. 
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RESULTS 
Safety and Tolerability  
Only patient 1 reported a mild AE (swelling and reddening at the r-hIL-7 injection 
site). No hematological or blood chemistry abnormalities were observed, and all 
compounds were tolerated well. 
Efficacy 
A clear reduction in the CSF JCV load was observed in both patients (Figure-A). JCV 
viral load testing remained negative during follow-up (12 months). Regarding MRI, no 
new T2 lesions were observed after treatment (Figure-B). Contrast-enhancing 
lesions never occurred in either patient before treatment over a 12 month period. 
After treatment we observed a subtle Gd-enhancing MRI lesion in patient 1, and 
clear enhancement in patient 2 indicative of an immune response in PML lesions 
(Figure-B). Clinically stabilization and/or amelioration of neurological findings after 
treatment was observed in both patients (see Scripps Neurological Rating Scale, 
SNRS, scores in Figure-C). Patient 1 significantly deteriorated during the twelve 
months between diagnosis and treatment (SNRS score dropped from 78 to 71). At 
the time of treatment he showed bilateral cerebellar signs of the lower limbs with gait 
ataxia and severe aphasia with leading comprehension deficits. Following treatment, 
he stabilized and perceptibly improved regarding cerebellar signs, speech and 
cognitive functions while remaining stable during follow-up (SNRS score 80). Patient 
2, who had steadily deteriorated before treatment developing left-sided hemiplegia 
and largely bedridden (SNRS score 49), stabilized clinically after treatment with signs 
of mild neuropsychological improvement regarding alertness (SNRS score 53). 
Finally, JCV VP1-specific CD4+ T cell responses served as mechanistic efficacy 
measure. Before treatment, PBMCs of both patients failed to respond to VP1 protein 
despite JCV infection. After treatment, proliferation of VP1-specific CD4+ T cells rose 
significantly in both patients (Figure-D). CFSE-labeled PBMCs from patient 1 after 
treatment and stimulated in vitro with VP1 confirmed that proliferating cells were 
mainly memory CD4+ T cells, although CD8+ T cell proliferation also rose 
(Supplementary Figure 1A). T cell responses to the recall antigen TTx were normal 
before treatment in patient 1 and remained unchanged at the end of treatment. In 
patient 2, TTx-specific CD4+ T cell responses were negative but turned positive after 
treatment most likely as an effect of immune reconstitution by r-hIL-7 (Figure-D). 
Supporting this notion the abnormally low CD4/CD8 ratio in both patients increased 
to normal levels after treatment (Supplementary Figure 1B). Intrathecal VP1-specific 
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antibody responses were elevated before treatment in both patients and did not 
change after treatment (Supplementary Figure 1C).  
  
 
DISCUSSION 
PML is often fatal in immunocompromised patients, and there is currently no 
treatment. Only immune reconstitution with r-hIL-7 (CYT107) represents an option 
based on preliminary data. Here, we performed two individual treatment attempts 
following ethical guidelines in two PML patients, who suffered from hereditary or 
acquired CD4 lymphopenia. Although these two PML cases could be seen as not 
sufficiently representative since they showed a longer survival than the majority of 
untreated PML patients, they significantly deteriorated during the twelve months 
between diagnosis and treatment. Due to the often fatal outcome of PML patients, 
they were treated with subcutaneous injections of r-hIL-7 (CYT107) with the aim to 
restore overall immune function. We have previously shown that JCV VP1-specific 
CD4+ T cells are highly enriched in the brain during PML-immune reconstitution 
inflammatory syndrome (IRIS) and probably critical for eliminating JCV from the CNS 
[3]. Since restoration of immune competence may not be sufficient to expand these 
JCV VP1-specific CD4+ T cells even in the presence of JCV and VP1 in the brain, we 
decided to also vaccinate patients with JCV VP1 protein via an immunogenic route, 
e.g. subcutaneously, in combination with a toll-like receptor 7 agonist as adjuvant in 
order to assure boosting of VP1-specific CD4+ T cell responses over other 
specificities. This PML treatment was not only well tolerated, but most importantly 
also appears to have long-lasting efficacy with respect to elimination of CSF JCV 
viral load, induction of MRI-proven inflammation at sites of PML lesions without 
prominent/classical PML-IRIS and clinical stabilization with slight improvement. This 
efficacy means that the two aims of our treatment, to restore overall immune 
responsiveness and to boost JCV VP1-specific CD4+ T cells, were accomplished. 
Immune restoration by r-hIL-7 was evident in patient 2, who had a low response to 
the recall antigen TTx and who regained responsiveness after treatment. Along this 
line, the peripheral CD4/CD8 ratio was also normalized after treatment in both 
patients. Further, CD4+ JCV VP1-specific T cell responses increased significantly 
from previously negative in both patients. Despite these encouraging results, 
additional investigation of treatment efficacy in PML patients with more severe 
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immunocompromise is warranted to discern the relative contribution of each 
compound and the putative role of VP1-specific CD8+ T cells. Furthermore, although 
this therapeutic approach is not suitable for HIV or monoclonal antibody treatment-
associated PML patients, in whom immune reconstitution is not the limiting factor, we 
believe that HIV patients or patients who will start on or are already treated with 
therapies that pose the risk of PML might benefit from a prophylactic vaccination with 
VP1. 
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FIGURE LEGEND 
Treatment Protocol (upper scheme). Dotted grey lines: time points of r-hIL-7 injection 
(patient 1: days -2 and 5; patient 2: days -2 and 7), solid grey lines represent time 
points of VP1 injection in combination with imiquimod (patient 1: days 0 and 41; 
patient 2: days 0 and 43), and black solid line represents simultaneous injection of 
VP1 and r-hIL-7 in combination with imiquimod (patient 1: day 12; patient 2: day 17). 
Day 0 is the day of the first VP1 injection. Subtle differences in schedule between the 
two patients were due to an intercurrent urinary tract infection in patient 2. A) JCV 
viral load in CSF from patient 1 (lower left graph) and patient 2 (lower right graph) 
before and at different time points during and after treatment. Graphs: y-axis 
represents viral load expressed as viral genome copies (GC)/mL and x-axis time in 
days. B) T2 MRI images from patient 1 (upper left) and patient 2 (upper right) before 
treatment and 12/14 months after treatment. Contrast-enhanced T1W MRI in patient 
1 (low left) and in patient 2 (low right) performed before and 40 days (patient 1) or 17 
days (patient 2) after first VP1 injection. White arrows point at Gd contrast-
enhancement indicative of neuroinflammation in the areas of PML lesions in both 
patients. The inset in the image of patient 1 focuses on the band-like Gd contrast-
enhancing lesion. (m=months, d=days) C) SNRS before treatment and 3 months and 
12/14 months after treatment. * Not available. D) JCV VP1- and TTx-specific CD4+ T 
cell responses before (month -1, white histograms), during (patient 1: day 12 and 41, 
patient 2: day 17 and 43; grey histograms) and after (day 84, black histograms) r-hIL-
7/JCV VP1 vaccination treatment. Proliferative responses were measured by 3H-
thymidine incorporation assay. Graphs (y-axis) represent SI (stimulation index). 
Mean ± SEM and statistical significance are shown, *p<0.05, **p<0.01 and 
***p<0.001. 
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